Genetically modified organisms to remediate polychlorinated biphenyls. Where do we stand?

被引:21
|
作者
Sylvestre, M [1 ]
机构
[1] INRS, Inst Armand Frappier, Pointe Claire, PQ H9R 1G6, Canada
关键词
PCB; dioxygenase; engineering catabolic pathway;
D O I
10.1016/j.ibiod.2004.03.011
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The biphenyl catabolic pathway transforms selected polychlorinated biphenyls (PCBs) to chlorobenzoates. The inability of bacteria to degrade the persistent PCBs is due to failure of enzymes of this pathway to catalyze their transformation. Biphenyl 2,3-dioxygenase (BPDO), 2,3-dihydroxybiphenyl 1,2-dioxygenase (HPDO) and 2-hydroxy-6-oxo-6-phenyl-2,4-hexadienoate (HOPDA) hydrolase (HOPDAH) are critical to deten-nine the range of PCBs degraded. Investigations are under way to examine features of these enzymes that influence their interactions with chlorinated substrates and to propose ways to bypass the blockages that they cause. BPDO terminal oxygenase component is an hexamer comprised of an alpha and a beta subunit. Burkholderia sp. LB400 and Pseudomonas pseudoalcaligenes KF707 BPDOs are very similar but exhibit quite distinct substrate specificities. Comainonas testosteroni B-356 and Rhodoccocus globerulus P6 BPDOs are more distantly related to LB400 BPDO and show a different range of PCB substrate used. Comparative analyses of the catalytic properties of chimeras of these enzymes unrevealed several regions of the C-terminal domain of the alpha subunit that strongly influence BPDO's substrate specificity. DNA shuffling between genes encoding these homologous BPDOs has been used to broaden the enzyme's substrate specificity. HPDOs are unable to oxygenate 3,4-dihydroxylated metabolites of chlorobiphenyls. HOPDAH are limited in their capacity to hydrolyze HOPDAs bearing chloro substituents on the dienoate inoiety. Enzymes homologous to HPDO and HOPDAH but exhibiting different patterns of substrate specificity have been identified. They provide tools to examine the enzymes structural features responsible for substrate specificity and to plan strategies to extend the range of chlorinated substrates that they can transforrn. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:153 / 162
页数:10
相关论文
共 50 条
  • [41] Toremifene:: where do we stand?
    Mäenpää, J
    Holli, K
    Pasanen, T
    EUROPEAN JOURNAL OF CANCER, 2000, 36 : S61 - S62
  • [42] Where do we stand on neuroprotection? Where do we go from here?
    Shoulson, I
    MOVEMENT DISORDERS, 1998, 13 : 46 - 48
  • [43] Treatment of negative symptoms: Where do we stand, and where do we go?
    Aleman, Andre
    Lincoln, Tania M.
    Bruggeman, Richard
    Melle, Ingrid
    Arends, Johan
    Arango, Celso
    Knegtering, Henderikus
    SCHIZOPHRENIA RESEARCH, 2017, 186 : 55 - 62
  • [44] THE DECADE OF TOTAL QUALITY - WHERE DO WE STAND - WHERE DO WE GO
    YEAGER, R
    PIMA MAGAZINE, 1994, 76 (03): : S2 - S3
  • [45] Occupational Rhinitis and Asthma: Where Do We Stand, Where Do We Go?
    Castano, Roberto
    Malo, Jean-Luc
    CURRENT ALLERGY AND ASTHMA REPORTS, 2010, 10 (02) : 135 - 142
  • [46] THE CYTOGENETICS OF RENAL TUMORS - WHERE DO WE STAND, WHERE DO WE GO
    WALTER, TA
    BERGER, CS
    SANDBERG, AA
    CANCER GENETICS AND CYTOGENETICS, 1989, 43 (01) : 15 - 34
  • [47] RED ALGAL SPECIES: WHERE DO WE STAND, WHERE DO WE GO?
    Zuccarello, G. C.
    PHYCOLOGIA, 2013, 52 (04) : 127 - 128
  • [48] Breast Cancer in India: Where Do We Stand and Where Do We Go?
    Khokhar, Anita
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (10) : 4861 - 4866
  • [49] Homocysteine research - where do we stand and where are we going?
    Herrmann, W
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2005, 43 (10) : 977 - 979
  • [50] Cushing disease: Where do we stand, where are we heading?
    Fleseriu, Maria
    Petersenn, Stephan
    PITUITARY, 2015, 18 (02) : 179 - 180